



UNIVERSITY OF MISSISSIPPI MEDICAL CENTER

Mississippi Cancer Registry Newsletter

In this issue:

Educational Corner

2018 Implementations

Upcoming webinars

CTR Maintenance

Congratulations!

Upcoming events

Merry Christmas!

Volume 13 Issue 4 December 21, 2018

MCR Staff

Occult Cervical Lymph Node

Beginning with cases diagnosed 1/1/2018 and later, for a head and neck primary lymph node involvement with no head and neck tumor found or specified by a physician (i.e., Occult Head and Neck Lymph Node), the primary site will be coded:

C76.0 if the neck node has not been tested or is negative for both HPV and EBV. The AJCC Cervical Lymph Nodes and Unknown Primary Tumor of the Head and Neck will be used.

C10.9 if the neck node is p16 positive indicating human papillomavirus (HPV). The AJCC HPV- Mediated (p16+) Oropharyngeal Cancer will be used.

C11.9 if the neck node is EBER positive, or both EBER and p16 positive, indicating Epstein Barr Virus (EBV). The AJCC Nasopharynx will be used.

Reference: STORE 2018, page 20-21;
NAACCR Pharynx 2018 Webinar

		EBV		
		Positive	Negative	Unknown
HPV (p16)	Positive	C11.9 Nasopharynx	C10.9 Oropharynx	C10.9 Oropharynx
	Negative	C11.9 Nasopharynx	C76.0 Ill-Defined Site of the Head and Neck	C76.0 Ill-Defined Site of the Head and Neck
	Unknown	C11.9 Nasopharynx	C76.0 Ill-Defined Site of the Head and Neck	C76.0 Ill-Defined Site of the Head and Neck

Abstracting

* When **using** the 2018 Solid Tumor Rules, code the most specific histology from either biopsy or resection. Do not code histology when described using any of the following modifiers or ambiguous

Modifiers	Ambiguous Terms
Architecture	Apparently
Differentiation	Appears
Features (of)	Comparable with
Foci, focus, focal	Compatible with
Major, majority of	Consistent with
Pattern(s)	Favor(s)
Predominantly	Malignant appearing
	Most likely
	Presumed
	Probable
	Suspect(ed)
	Suspicious (for)
	Typical (of)

2018 Solid Tumor Rules

Module Updates:

Malignant CNS and Peripheral Nerves - updated **10/12/2018**

Non-Malignant CNS Tumors - updated **10/12/2018**

Lung - updated **10/12/2018**

Thyroid AJCC Clinical Staging

Imaging and confirmation = clinical stage

Imaging then surgery = no clinical stage

Reference: AJCC 7th Edition

2018 Implementations

AJCC Cancer Staging Manual

Cases with a diagnosis date of 01/01/2018 and forward should be staged using AJCC 8th Edition Cancer Staging Manual. The 3rd printing 2018 Edition is now available. The eBook is coming in 2018.

- Please visit <https://cancerstaging.org/references-tools/deskreferences/Pages/8EUpdates.aspx#> for all 8th Edition updates and corrections. For all other information, visit <https://cancerstaging.org/Pages/default.aspx>.

Summary Stage 2018

The 2018 version of Summary Stage applies to every site and/or histology combination, including lymphomas and leukemias. Summary Stage uses all information available in the medical record; in other words, it is a combination of the most precise clinical and pathological documentation of the extent of disease. The Summary Stage 2018 manual is available at <https://seer.cancer.gov/tools/ssm/>.

Site Specific Data Items (SSDI)

Site Specific Data Items (SSDI) are similar to the Site Specific Factors (SSF) collected with Collaborative Stage. These data items are specific to certain site/histology combinations. For example, the SSDI's for breast will be used to collect information such as estrogen receptor status, progesterone receptor status, Her2 status, Nottingham grade, and additional information related to primary tumors of the breast. The information collected in these data items are specific to breast. The SSDI manual is available at <https://apps.naaccr.org/ssdi/list/>.

Grade

Beginning with cases diagnosed in 2018 grade information will be collected in three fields; Clinical Grade, Pathological Grade, and Post-Therapy Grade. Within the Grade Manual you will find definitions for the three new grade data items, coding instructions, and the site/histology specific grade tables. The Grade manual is available at <https://www.naaccr.org/SSDI/Grade-Manual.pdf?v=1527859766>.

SEER Hematopoietic and Lymphoid Neoplasm Database

This provides data collection rules for hematopoietic and lymphoid neoplasms for 2010+. The SEER Hematopoietic and Lymphoid Neoplasm manual is available at [https://seer.cancer.gov/tools/heme/Hematopoietic Instructions and Rules.pdf](https://seer.cancer.gov/tools/heme/Hematopoietic%20Instructions%20and%20Rules.pdf).

2018 Solid Tumor Coding Manual

Use the 2018 Solid Tumor coding rules to determine the number of primaries to abstract and the histology to code for cases diagnosed 2018 and forward. The Solid Tumor coding rules replace the [2007 Multiple Primary and Histology \(MP/H\) Rules](#). The is available at <https://seer.cancer.gov/tools/solidtumor/>. The [change log](#) contains updates made to the FINAL module sections. This does not include changes made to the drafts.

CoC 2018 STORE Manual

The STORE Manual has replaced the FORDS Manual. The STORE is now available at <https://www.facs.org/quality-programs/cancer/ncdb/registrymanuals/cocmanuals>.



North American Association of Central Cancer Registries

Upcoming Webinars

- | | |
|---------|--------------------------------|
| 1/10/19 | Collecting Cancer Data: Testis |
| 2/7/19 | Collecting Cancer Data: Colon |
| 3/7/19 | Boot Camp |

For more information contact: La'Tawnya Roby, BS, CTR ldroby@umc.edu

<https://www.naacrr.org/>

CTR Maintenance



CE Requirements

Certified Tumor Registrars (CTR) must complete a minimum of 20 hours of continuing education (CE) to maintain a certified status. The required 20 CEs helps keep CTRs current on new developments in the field of oncology and registry data management. At least four (4) of the required 20 CE hours must fall within "Category A" which covers the specific topic(s) of: directly assigned stage and/or site specific coding principles.

<http://www.ncra-usa.org/Portals/68/PDFs/CategoryA-CTR-FAQ.pdf?ver=2017-05-16-213728-470>

Examples for Category A are activities that:

- # Demonstrate assigning AJCC stage
- # Describe information needed to assign SEER Summary Stage
- # Analyze the changes from AJCC 7th edition to AJCC 8th edition
- # Discuss the rules from staging using AJCC with edition staging manual
- # Discuss site-specific AJCC or SEER Summary staging

2019 Membership Renewal is Underway!

<http://www.ncra-usa.org/Membership/Renew>

Congratulations

New Certified Tumor Registrars

Natasha Bullock, UMMC Cancer Registry

Great job, on passing the CTR exam!



UPCOMING EVENTS


mark your calendars



MCRA Spring Educational Meeting

April 2019

For information, contact Beth Pennington, at npennington@mhg.com



APR 8-12 2019

NATIONAL CANCER REGISTRARS WEEK
CANCER REGISTRARS: CAPTURING THE PICTURE OF CANCER



NCRA's 2019 ANNUAL EDUCATIONAL CONFERENCE
May 19-22, 2019 | Denver, CO

**CALL FOR ABSTRACTS
NOW OPEN!**



NAACCR • IACR

VANCOUVER 2019

The North American Association of Central Cancer Registries (NAACCR) is pleased to invite you to attend the combined conference of NAACCR and IACR (International Association of Cancer Registries) for 2019. The conference will take place June 8 – 13, 2019, in Vancouver, British Columbia, Canada.



MCRA Fall Educational Workshop

September 19, 2019

For more information contact: La'Tawnyia Roby, BS, CTR ldroby@umc.edu



Christmas at MCR and UMMC



Director– UMMC & MS Cancer Registry:

Deirdre Rogers, dbrogers@umc.edu

MCR Manager:

Tresheena Boyd, tboyd@umc.edu

Clinical Systems-Application Coordinator/Analyst-

Intermediate:

Kristy Brister, kabrister@umc.edu

Data Analyst-Auditor:

Ashanti Greenwood, agreenwood@umc.edu

Data Analyst-Trainer:

La'Tawnya Roby, ldroby@umc.edu



UNIVERSITY OF MISSISSIPPI

MEDICAL CENTER

2500 NORTH STATE STREET

JACKSON, MISSISSIPPI 39216

Phone: 601-815-5482

Fax: 601-815-5483

<https://www.umc.edu/mer/>

Cancer Registrars:

Deidra Amos, damos@umc.edu

Stacy Major, semajor@umc.edu

April Huggins, ahuggins@umc.edu

Lisa Hamel, lhamel@umc.edu

Nina Engelman, nengelman@umc.edu

Administrative Assistant:

Ophelia Spencer, ospencer@umc.edu



We acknowledge the Centers for Disease Control and Prevention and University of Mississippi Medical Center for their support of the MCR staff, and the printing and distribution of the monograph under a cooperative agreement awarded to the MCR.